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Striatal functions depend on the activity balance between the dopamine and glutamate
neurotransmissions. Glutamate inputs activate cyclin-dependent kinase 5 (Cdk5), which
inhibits postsynaptic dopamine signaling by phosphorylating DARPP-32 (dopamine- and
cAMP-regulated phosphoprotein, 32 kDa) at Thr75 in the striatum. c-Abelson tyrosine
kinase (c-Abl) is known to phosphorylate Cdk5 at Tyr15 (Tyr15-Cdk5) and thereby facilitates
the Cdk5 activity. We here report that Cdk5 with Tyr15 phosphorylation (Cdk5-pTyr15) is
enriched in the mouse striatum, where dopaminergic stimulation inhibited phosphorylation
of Tyr15-Cdk5 by acting through the D2 class dopamine receptors. Moreover, in the
1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine (MPTP) mouse model, dopamine deficiency
caused increased phosphorylation of both Tyr15-Cdk5 and Thr75-DARPP-32 in the
striatum, which could be attenuated by administration of L-3,4-dihydroxyphenylalanine
and imatinib (STI-571), a selective c-Abl inhibitor. Our results suggest a functional link of
Cdk5-pTyr15 with postsynaptic dopamine and glutamate signals through the c-Abl kinase
activity in the striatum.
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INTRODUCTION
Cyclin-dependent kinase 5 (Cdk5) is a member of the Cdk fam-
ily of serine/threonine kinases and is abundantly expressed in
the brain (Dhavan and Tsai, 2001). Besides the essential role of
Cdk5 in neuronal positioning and synaptogenesis during brain
development, Cdk5 has also been involved in the cell signal-
ing and survival in adult brains (Dhavan and Tsai, 2001; Smith
and Tsai, 2002; Dhariwala and Rajadhyaksha, 2008; Hisanaga
and Endo, 2010). In the striatum, Cdk5 plays a regulatory role
in the dopamine and glutamate transmissions that are inte-
grated by DARPP-32 (dopamine- and cAMP-regulated phospho-
protein, 32 kDa) (Greengard, 2001). Glutamate inputs activate
Cdk5, which inhibits postsynaptic dopamine D1 receptor (D1R)-
mediated signaling by phosphorylating DARPP-32 at Thr75
(Thr75-DARPP-32) in the striatum, since DARPP-32 with Thr75
phosphorylation (DARPP-32-pThr75) functions as an inhibitor
of cAMP-dependent protein kinase A (PKA). Dysregulation of
Cdk5 activity has been implicated in striatal dopamine disorders
that include Parkinson’s disease (PD) (Chergui et al., 2004) and
drug addiction (Bibb et al., 2001; Takahashi et al., 2005); how-
ever, it is not fully understood how Cdk5 interacts with dopamine
signaling in the striatum.
One of the regulatory mechanisms that modulate the Cdk5
kinase activity is phosphorylation of conserved residues (Dhavan
and Tsai, 2001). c-Abelson kinase (c-Abl), a non-receptor tyro-
sine kinase related to the Src family, is the known kinase
that phosphorylates Cdk5 at Tyr15 (Tyr15-Cdk5) and thereby
increases its kinase activity (Zukerberg et al., 2000; Dhavan and
Tsai, 2001; Zhang et al., 2007). Impaired activity of c-Abl partic-
ipates in the pathogenesis of several neurodegenerative diseases
(Schlatterer et al., 2011). We recently found that Cdk5 with phos-
phorylation of Tyr15 (Cdk5-pTyr15) is enriched in the striatum
(Morigaki et al., 2011). This strategic localization of Cdk5-pTyr15
suggests a possible role of the c-Abl/Cdk5 signaling in modula-
tion of postsynaptic dopamine and glutamate transmissions in
the striatum.
Here, we show that in the mouse striatum, dopamine
receptor stimulation negatively regulates phosphorylation of
Tyr15-Cdk5 most likely through a D2R-mediated mechanism.
We also provide an evidence that in the 1-methyl-4-phenyl-
1,2,4,6-tetrahydropyridine (MPTP) mouse model with striatal
dopamine deficiency, a c-Abl kinase inhibitor imatinib (STI-571)
(Capdeville et al., 2002) attenuates abnormally increased stri-
atal phosphorylation of both Tyr15-Cdk5 and Thr75-DARPP-32,
as does L-3,4-dihydroxyphenylalanine (L-dopa). These findings
have important implications for understanding the mechanisms
by which the Cdk5/DAPP-32-Thr75 signaling regulates the stri-
atal functions.
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MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
All procedures involving experimental mice were approved by
the Ethical Review Committee of the University of Tokushima.
Male C57BL/6 mice aged at 8–9 weeks (Nihon SLC Co., Shizuoka,
Japan) were used. Mice were housed under a 12 h-light and 12
h-dark cycle with access to food and tap water ad libitum. The
total number of mice used in this study was 350.
MPTP ADMINISTRATION
Mice were injected intraperitoneally 4 times in one day with
MPTP hydrochloride (20mg/kg of free base; Sigma–Aldrich, St
Louis, MO) at 2 h intervals (Yokoyama et al., 2010). Saline-treated
mice received an equivalent volume of 0.9% saline. Our previous
study showed that maximal neurodegenerative effects of MPTP
on the nigral dopaminergic cells were observed at the 3 days
time-point after administration of MPTP (Aoki et al., 2009).
L-dopa ADMINISTRATION
Mice received single intraperitoneal injections of L-dopa
hydrochloride (15mg/kg of free base; Sigma-Aldrich) dissolved
in 0.9% saline containing 0.5% carboxymethyl cellulose 3 days
after administration of MPTP or saline. The used dose of L-dopa
was chosen based on the findings reported previously (Chartoff
et al., 2001). Vehicle-treated mice received an equivalent vol-
ume of 0.9% saline containing 0.5% carboxymethyl cellulose.
They were pre-treated with single intraperitoneal injections of
benserazide (12.5mg/kg; Sigma–Aldrich) dissolved in 0.9% saline
20min before administration of L-dopa or vehicle.
IMATINIB ADMINISTRATION
Mice received single intraperitoneal injections of imatinib mesy-
late (25mg/kg; LKT Laboratories, St. Paul, MN) dissolved in 0.9%
saline containing 10% dimethylsulfoxide 3 days after admin-
istration of MPTP or saline. Vehicle-treated mice received an
equivalent volume of 0.9% saline containing 10% dimethylsul-
foxide.
WESTERN BLOT ANALYSIS
Mice were sacrificed by cervical dislocation 30min after intraperi-
toneal administration of apomorphine hydrochloride, (5 or
10mg/kg of free base; Sigma–Aldrich), A-68930 hydrochloride
(2mg/kg of free base; Sigma–Aldrich), SCH-23390 hydrochloride
(0.5mg/kg of free base; Sigma–Aldrich), quinpirole hydrochlo-
ride (5mg/kg of free base; Sigma–Aldrich), raclopride tartrate
(1mg/kg of free base; Sigma–Aldrich), L-dopa (15mg/kg) with
benserazide (12.5mg/kg), or imatinib mesylate (25mg/kg or
10mg/kg). Western blot analysis was carried out according
FIGURE 1 | Localization of Cdk5-p Tyr15 in the mouse striatum.
(A) Photomontage of parasagittal brain sections stained for
Cdk5-pTyr15. (B) Photomicrograph of a striatal section stained for
Cdk5-pTyr15. Note that the matrix compartment is enriched in
Cdk5-pTyr15 as compared to the striosomes. The asterisk indicates an
example of striosomes poor in Cdk5-pTyr15 labeling. (C–C”) Double
immunofluorescence staining for Cdk5-pTyr15 (C) and MOR (C’), and
merged (C”). A corresponding striosome is indicated by the asterisks.
(D and E) Photomicrographs of striatal neurons immunoreactive for
Cdk5-pTyr15. Cdk5-pTyr15 labeling is found in neuronal soma,
processes, and nuclei of striatal neurons. Scale bars: (A), 1mm; (B)
and (C–C”), 500μm; (D), 20μm; (E), 5μm.
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FIGURE 2 | Dopamine receptor stimulation inhibits striatal
phosphorylation of Cdk5 at Tyr15. (A) Western blot analysis on the
effects of apomorphine on striatal levels of Cdk5-pTyr15. Mice received
saline or the indicated amounts of apomorphine 30min before sacrifice.
Values are means±S.E.M. (n = 5). ∗P < 0.005 versus saline-treated
mice; two tailed Student’s t-test. (B–D) Immunohistochemical
assessment of the effects of apomorphine on striatal density of
Cdk5-pTyr15 labeling. (B–B”) Frontal sections stained for Cdk5-pTyr15 in
the anterior (B; 1.3mm anterior to bregma), middle (B’; 1.0mm anterior
to bregma), and posterior (B”; 0.1mm posterior to bregma) levels of
the striatum from a saline-treated mouse. (C–C”) Frontal sections
stained for Cdk5-pTyr15 in the rostral (C; 1.3mm anterior to bregma),
middle (C’; 1.0mm anterior to bregma), and caudal (C”; 0.1mm
posterior to bregma) levels of the striatum from an apomorphine-treated
mouse. (D) Optical density measurements of striatal Cdk5-pTyr15
labeling in saline- and apomorphine-treated mice. Values are
means±S.E.M. (n = 5). *P < 0.005 versus saline-treated mice;
two-tailed Student’s t-test.
to the method described previously (Kasahara et al., 2001).
Briefly, striatal tissue samples from deeply anesthetized mice
were homogenized in 50mM Tris-HCl buffer, pH 7.5, contain-
ing 0.5M NaCl, 0.5% Triton X-100, 10mM EDTA, 4mM EGTA,
1mMNa3VO4, 30mMNa4P2O7, 50mMNaF, 0.1mM leupeptin,
0.075mM pepstatin A, 0.05mg/ml trypsin inhibitor, 1mM
phenylmethanesulfonyl fluoride, 100 nM calyculin A, and 1mM
dithiothreitol. After centrifugation at 21,500× g for 10min, the
protein lysates were resuspended in 100mM NaH2PO4, pH 6.0,
ImM EDTA, 1% 2-mercaptoethanol, 0.1% sodium dodecyl sul-
fate, to 1mg/ml final protein concentration and was heated
at 99◦C for 3min. Specific antibodies against Cdk5-pTyr15
(1:1000; Abcam, Cambridge, UK), Cdk5 (1:1000; Santa Cruz
Biotechnology, Santa Cruz, CA), DARPP-32-pThr75 (1:1000;
Cell Signaling, Danvers, MA), DARPP-32-pThr34 (1:1000; Cell
Signaling), DARPP-32 (1:1000; Cell Signaling) were used. The
monospecificity of these antibodies was confirmed in our pre-
vious reports (Sako et al., 2010; Morigaki et al., 2011). Anti-β-
actin antibody (1:1000; Sigma–Aldrich) was used to adjust equal
amounts of protein loading into each well. Gel images were cap-
tured using a lumino-imaging analyzer LAS-4000 (Fuji, Tokyo,
Japan). Optical densities were determined using a computerized
image analysis system (Dolphin-DOC; Kurabo, Osaka, Japan)
(Yokoyama et al., 2010).
TISSUE PREPARATION AND IMMUNOSTAINING
Mice were injected intraperitoneally with a lethal dose of pen-
tobarbital (Sigma, St Louis, MO) 30min after drug admin-
istration. They were then transcardially perfused with 0.01M
phosphate-buffered saline (PBS) at pH 7.4, followed by cold
4% paraformaldehyde in 0.1 M phosphate buffer (PB) at pH
7.4. The brains were removed, post-fixed overnight in the
same fixative at 4◦C, and stored in a 10–30% sucrose gradi-
ent in 0.1M PB at 4◦C for cryoprotection. Sections were cut
on a cryostat at 15μm-thickness, and stored in PBS contain-
ing 0.05% NaN3 until use. Immunofluorescence staining was
carried out with free-floating brain sections (Morigaki et al.,
2011). Primary antibodies against Cdk5-pTyr15 (1:20,000; Santa
Cruz), tyrosine hydroxylase (TH, 1:100,000) (Sato et al., 2008),
and DARPP-32-Thr75 (1:20,000; Cell Signaling) (Sako et al.,
2010) were used. The bound primary antibodies were detected
using the Histofine Simple Stain Kit (Nichirei, Tokyo, Japan)
and Tyramide Signal Amplification (TSA) system with Cyanine3
or Fluorescein (Perkin Elmer, Shelton, CT) (Morigaki et al.,
2011).
For double immunofluorescence staining Cdk5-pTyr15 and
μ-opioid receptor (MOR), dual antigen detection with the
TSA system was carried out according to the method that we
reported previously (Okita et al., 2012). Briefly, sections were
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FIGURE 3 | Negative regulation of striatal phosphorylation of Tyr15-Cdk5
through a D2R-mediated mechanism. Western blot analysis was carried
out on the striatal extracts from mice that received saline, A-68930 (2mg/kg),
SCH-23390 (0.5mg/kg), quinpirole (5mg/kg), or raclopride (1mg/kg), 30min
before sacrifice. Effects of administration of A-68930 (A), SCH-23390 (B),
quinpirole (C), or raclopride (D), on striatal levels of Cdk5-pTyr15 are shown.
Values are means ±S.E.M. (n = 5). ∗P < 0.005 versus saline-treated mice;
two tailed Student’s t-test.
first incubated in PBS containing 3% BSA and anti-Cdk5-
pTyr15 antibodies (1:20,000; Santa Cruz). The bound primary
antibodies were detected by the Histofine Simple Stain Kit
(Nichirei, Tokyo, Japan) and the TSA system with Cyanine3
(Perkin Elmer). To remove the bound antibodies, the stained
sections were then incubated in 0.1M glycine-HCl (pH 2.2)
at room temperature for 30min. After incubation in PBS for
1 h, the sections were incubated in PBS containing 3% BSA
and antibodies for MOR (1:100,000; Millipore, St. Louis, MO,
USA). The bound antibodies were detected by the Histofine
Simple Stain Kit (Nichirei) and the TSA system with Fluorescein
(Perkin Elmer).
DIGITAL IMAGING AND DENSITOMETRY
Digital microscopic images were captured using an Olympus
BX51microscope (Olympus, Tokyo, Japan), imported into Adobe
Photoshop CS4, and processed digitally. The optical densities
of immunoreactive products were measured as gray levels on
non-colored digital images (Sato et al., 2008; Morigaki et al.,
2011). For each animal (n = 5), density measurement was made
in a striatal section at the level of 0.9–1.1mm anterior to bregma,
according to the atlas of Hof et al. (2000).
STATISTICAL ANALYSIS
All experimental values were expressed as means± S.E.M.
Statistical significance was evaluated by two-tailed Student’s
t-test, or One-Way ANOVA with Bonferroni–Dunn or Fisher’s
PLSD post hoc test. The significance level was set at P < 0.05.
RESULTS
ENRICHMENT OF Cdk5-pTyr15 IN THE STRIATUM
We first determined the localization pattern of Cdk5-pTyr15
in the brain of mice used in this study. Among brain regions,
strong Cdk5-pTyr15 labeling was found in the striatum that
consists of the dorsal striatum (caudoputamen), nucleus accum-
bens and olfactory tubercle (Figure 1A). In the dorsal striatum,
Cdk5-pTyr15 immunostaining exhibited an inhomogeneous dis-
tribution with heightened labeling in the matrix compartment
relative to the striosomes (Figures 1B,C). At the cellular level
(Figures 1D,E), Cdk5-pTyr15 immunoreactivity was found in
neuronal soma, processes, and nuclei of striatal neurons. Thus,
Cdk5-pTyr15 appears as a striatal-enriched phosphoprotein, as
does DARPP-32 (Ouimet et al., 1998).
DOPAMINE RECEPTOR STIMULATION INHIBITS STRIATAL
PHOSPHORYLATION OF Cdk5 AT Tyr15
To test whether striatal phosphorylation of Tyr15-Cdk5 was
altered by dopaminergic stimulation, we performed the western-
blot assay for Cdk5-pTyr15 expression after treatment with
apomorphine, an agonist for both the D1Rs and D2Rs. A sig-
nificant reduction of the striatal levels of Cdk5-pTyr15 was
found following administration of apomorphine at a dose of
5mg/kg or 10mg/kg (Figure 2A; P < 0.005, Student’s t-test).
Immunohistochemical study on frontal sections from anterior
to posterior of the forebrain also showed a decreased den-
sity of Cdk5-pTyr15 staining in the striatum of mice that
received apomorphine (10mg/kg) (Figures 2B,C). Densitometric
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FIGURE 4 | Loss of dopaminergic inputs and increased
phosphorylation of Tyr15-Cdk5 in the striatum in MPTP mice. Striatal
sections were prepared and subjected to the immunohistochemical study
(see “Materials and Methods”). (A–C) Severe loss of TH-immunoreactive
afferents in the striatum in MPTP mice. Representative images of striatal
sections (0.0–1.0mm anterior to bregma) immunostained for TH from
saline- (A) and MPTP-treated (B) mice. (C) Optical density measurements
of striatal TH labeling in saline- and MPTP-treated mice. Values are
means ±S.E.M. (n = 5). ∗P < 0.001 versus saline-treated mice, two tailed
Student’s t-test. (D–F) Increased density of striatal Cdk5-pTyr15 labeling
in MPTP mice. Representative images of striatal sections (0.0–1.0mm
anterior to bregma) immunostained for Cdk5-pTyr15 from saline- (D) and
MPTP-treated (E) mice. (F) Optical density measurements of striatal
Cdk5-pTyr15 labeling in saline- and MPTP-treated mice. Values are
mean±S.E.M. (n = 5). ∗P < 0.01 versus saline-treated mice, two tailed
Student’s t-test.
measurements confirmed this (Figure 2D; P < 0.005, Student’s
t-test). We next examined whether dopaminergic stimulation
could cause reduced expression of Cdk5-pTyr15 by acting on
the D1 or D2 class receptors (Figure 3). Western blot anal-
ysis revealed no apparent changes in the striatal levels of
Cdk5-pTyr15 following administration of a D1 receptor ago-
nist A-68930 (2mg/kg) (Figure 3A; P > 0.05, Student’s t-test),
or a D1 receptor antagonist SCH-23390 (0.5mg/ml) (Figure 3B;
P > 0.05, Student’s t-test). By contrast, striatal levels of Cdk5-
pTyr15 were significantly decreased following administration of a
D2 receptor agonist quinpirole (5mg/kg) (Figure 3C; P < 0.005,
Student’s t-test), and they were significantly increased following
administration of a D2 receptor antagonist raclopride (1mg/kg)
(Figure 3D; P < 0.005, Student’s t-test). These findings sug-
gest that dopamine signal can inhibit striatal phosphorylation
of Tyr15-Cdk5 and this process most likely occurs through a
D2R-mediated mechanism.
L-dopa EFFECTS ON STRIATAL PHOSPHORYLATION OF Cdk5 AND
DARPP-32 IN MPTP MICE
To gain further insight into the interactions between the
c-Abl/Cdk5 signaling and the dopamine and glutamate
signal cascades, we conducted an experiment in MPTP mice.
Immunohistochemical study revealed severe loss of dopaminer-
gic afferents labeled for TH in the striatum of the MPTP mice
(Figures 4A–C). By contrast, an increased density of Cdk5-
pTyr15 labeling in the striatum was found in MPTP mice when
compared with control mice (Figures 4D–F; P < 0.01, Student’s
t-test). It was evident in the entire striatum that includes dorsal
striatum, nucleus accumbens and olfactory tubercle. Western
blot analysis also revealed a significant increase in the striatal
levels of Cdk5-pTyr15 (Figure 5A; P < 0.005, ANOVA), but
not Cdk5 (Figure 5A; P > 0.05, ANOVA), in MPTP mice as
compared to saline-treated mice. It was also noted that in MPTP
mice L-dopa treatment significantly attenuated the abnormally
elevated striatal levels of Cdk5-pTyr15 (Figure 5A; P < 0.005,
ANOVA). This antagonistic action of L-dopa on striatal phos-
phorylation of Tyr15-Cdk5 in MPTP mice was also found in the
immunohistochemical assessment (Figure 5B).
We next examined on striatal phosphorylation of DARPP-32
in MPTP mice (Figures 5C,D). Western blot analysis revealed a
significant increase in striatal phosphorylation of DARPP-32 at
Thr75, the substrate site targeted by Cdk5, in MPTP mice, as
compared to saline-treated mice (Figure 5C; P < 0.05, ANOVA).
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FIGURE 5 | Effects of L-dopa on striatal phosphorylation of Cdk5 and
DARPP-32 in MPTP mice. Saline- or MPTP-treated mice received vehicle or
L-dopa 30min before sacrifice. Striatal tissue extracts and sections were
prepared and subjected to western blotting and immunohistochemical
staining (see “Materials and Methods”). (A) Western blot analysis of striatal
(Continued)
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FIGURE 5 | Continued
levels of Cdk5-pTyr15 and Cdk5 in mice treated with saline + vehicle,
saline + L-dopa, MPTP + vehicle, or MPTP + L-dopa. Values are
means±S.E.M. (n = 5–6). ∗P < 0.001 versus mice treated with saline
+ vehicle, saline + L-dopa, or MPTP + L-dopa; One-Way ANOVA
[F(3.18) = 31.06] followed by Bonferroni–Dunn test. (B)
Immunohistochemical study on striatal labeling for Cdk5-pTyr15 in mice
treated with saline + vehicle, saline + L-dopa, MPTP + vehicle, or
MPTP + L-dopa. Representative images of the striatal sections
(0.0–1.0 mm anterior to bregma) stained for Cdk5-pTyr15 from each
group are shown. Densitometric analysis was made on a striatal
section from each mouse in a group of saline + vehicle, saline +
L-dopa, MPTP + vehicle or MPTP + L-dopa. Values are
means±S.E.M. (n = 5). ∗P < 0.005 versus mice treated with saline +
vehicle, saline + L-dopa, or MPTP + L-dopa; One-Way ANOVA
[F(3.16) = 26.84] followed by Fisher’s PLSD test. (C) Western blot
analysis of striatal levels of DARPP-32-pThr75, DARPP-32-pThr34, and
DARPP-32 in mice treated with saline + vehicle, saline + L-dopa,
MPTP + vehicle, or MPTP + L-dopa. Values are means±S.E.M.
(n = 4–7). ∗P < 0.01 versus mice treated with saline + vehicle,
saline + L-dopa, or MPTP + L-dopa; One-Way ANOVA [F(3.18) = 6.96]
followed by Bonferroni–Dunn test. (D) Immunohistochemical study on
striatal labeling for DARPP-32-pThr75 in mice treated with saline +
vehicle (n = 5), saline + L-dopa (n = 5), MPTP + vehicle (n = 5), or
MPTP + L-dopa (n = 5). Representative images of the striatal sections
(0.0–1.0mm anterior to bregma) stained for DARPP-32-pThr75 from
each group are shown. Densitometric analyses were made on a
striatal section from each mouse in a group of saline + vehicle,
saline + L-dopa, MPTP + vehicle or MPTP + L-dopa. Values are
means±S.E.M (n = 5). ∗P < 0.005 versus mice treated with saline +
vehicle, saline + L-dopa, or MPTP + L-dopa; One-Way ANOVA
[F(3.16) = 19.62] followed by Fisher’s PLSD test.
No apparent difference in striatal levels of DARPP-32-pThr34
(Figure 5C; P > 0.05, ANOVA) and DARPP-32 (Figure 5C; P >
0.05, ANOVA) was found between theMPTPmice and the saline-
treated mice. L-Dopa treatment significantly reduced the abnor-
mally elevated striatal levels of DARPP-32-pThr75 in MPTP mice
(Figure 5C; P < 0.05, ANOVA). Immunohistochemical analysis
also documented that L-dopa reversed increased density of striatal
labeling for DARPP-32-pThr75 in MPTP mice (Figure 5D).
IMATINIB EFFECTS ON STRIATAL PHOSPHORYLATION OF Tyr15-Cdk5
AND Thr75-DARPP-32 IN MPTP MICE
We next asked if a selective c-Abl inhibitor imatinib (STI-571)
could modulate striatal phosphorylation of Cdk5 and DARPP-32.
Western blot analysis revealed that in MPTPmice abnormally ele-
vated striatal levels of Cdk5-pTyr15 was significantly attenuated
by administration of imatinib at a dose of 25mg/kg (Figure 6A;
P < 0.005, ANOVA), but not 10mg/kg (data not shown). This
was consistent with the results obtained with immunohistochem-
istry (Figure 6B). Imatinib treatment also significantly attenu-
ated abnormally increased striatal levels of DARPP-32-pThr75
in MPTP mice, as determined by western blot (Figure 6C; P <
0.05, ANOVA) and immunohistochemical (Figure 6D; P < 0.05,
ANOVA) analyses.
Taken together, dopamine deficiency caused an increased
phosphorylation of both Tyr15-Cdk5 and Thr75-DARPP-32 in
the striatum, which could be ameliorated by administration of
L-dopa and imatinib.
DISCUSSION
In this study, we demonstrate a functional link of Cdk5-pTyr15,
a striatal-enriched phosphoprotein, with postsynaptic dopamine
and glutamate signal cascades in the striatum. Striatal func-
tions depend on an activity balance between dopamine and
glutamate transmissions that produce opposing physiological
effects (Greengard, 2001; Chergui et al., 2004) (for reference
see Figure 7). DARPP-32 integrates the activities of dopaminer-
gic and glutamatergic transmissions (Svenningsson et al., 2004;
Fernandez et al., 2006), and it is therefore thought to play as
a key regulator for striatal activities (Bonito-Oliva et al., 2011).
This striatal-enriched protein can function as either a pro-
tein phosphatase inhibitor or a kinase inhibitor, depending on
whether Thr34-DARPP-32 or Thr75-DARPP-32 is phosphory-
lated (Greengard, 2001; Yger and Girault, 2011). In this scenario,
glutamate inputs are thought to exert an antagonistic action on
postsynaptic dopamine signaling by activating Cdk5 to phos-
phorylate Thr75-DARPP-32 in the striatum. DARPP-32-pThr75
functions as an inhibitor of PKA that is a key mediator of the
D1R-signals. We here showed that the c-Abl inhibitor imatinib
attenuated abnormally elevated striatal levels of Cdk5-pTyr15 and
DARPP-32-pThr75 in MPTP mice, as did L-dopa. As c-Abl is
the known kinase that phosphorylate Tyr15-Cdk5 (Zukerberg
et al., 2000; Dhavan and Tsai, 2001; Zhang et al., 2007), these
observations suggest an involvement of the c-Abl/Cdk5-pTyr15
signaling in the mechanism by which glutamate inputs acti-
vate Cdk5 to increase phosphorylation of Thr75-DARPP-32. Our
present data also indicate that dopamine receptor stimulation
negatively regulates the glutamate/Cdk5 cascade by inhibiting
striatal phosphorylation of Tyr15-Cdk5; this process most likely
occurs through a D2R-mediated mechanism. This might be in
accordance with the reported findings that by acting through the
D2Rs, dopamine signaling reduces presynaptic glutamate release
and it also attenuates postsynaptic cellular responsiveness to glu-
tamate receptor stimulation in the striatum (Surmeier et al.,
2007). However, it is currently unknown how glutamate inputs
activate c-Abl to increase striatal phosphorylation of Cdk5 on
Tyr15. Identification of the molecular basis for the glutamate-
mediated activation of c-Abl kinase in the striatum might remain
an intriguing possibility.
Among striatal disorders, PD is a representative movement
disorder that results from striatal dopamine deficiency. In the
striatum under resting conditions, Thr75-DARPP-32 is highly
phosphorylated, whereas Thr34-DARPP-32 is only slightly phos-
phorylated (Greengard, 2001; Sako et al., 2010). This suggests that
tonic activity of the glutamate/Cdk5 pathway might be respon-
sible for maintaining Thr75-DARPP-32 in a phosphorylated
state, thereby inhibiting the D1R-PKA signaling in the striatum
(Greengard, 2001). In addition, landmark reports showed that
in a rodent model of PD, striatal dopamine deficiency had no
effect on phosphorylation of Thr34-DARPP-32, but significantly
increased that of Thr75-DARPP-32 (Brown et al., 2005; Santini
et al., 2007), as we observed here in the MPTP mice. These find-
ings suggest that the glutamate/Cdk5/DARPP-32-Thr75 pathway
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FIGURE 6 | Effects of imatinib on striatal phosphorylation of Cdk5 and
DARPP-32 in MPTP mice. Saline- or MPTP-treated received vehicle or
imatinib 30min before sacrifice. Striatal tissue extracts and sections were
prepared and subjected to western blotting and immunohistochemical
staining (see “Materials and Methods”). (A) Western blot analysis of striatal
(Continued)
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FIGURE 6 | Continued
levels of Cdk5-pTyr15 and Cdk5 in mice treated with saline + vehicle,
saline + imatinib, MPTP + vehicle, or MPTP + imatinib. Values are
mean ±S.E.M. (n = 4–5). ∗P < 0.05 versus mice treated with saline +
vehicle, saline + imatinib, or MPTP + imatinib; One-Way ANOVA [F(3.14) =
9.28] followed by Bonferroni–Dunn test. (B) Immunohistochemical study
on striatal labeling for Cdk5-pTyr15 in mice treated with saline + vehicle,
saline + imatinib, MPTP + vehicle or MPTP + imatinib. Representative
images of the striatal sections (0.0–1.0mm anterior to bregma) stained
for Cdk5-pTyr15 from each group are shown. Densitometric analyses
were made on a striatal section from each mouse in a group of saline +
vehicle, saline + imatinib, MPTP + vehicle or MPTP + imatinib. Values
are means ±S.E.M. (n = 5). ∗P < 0.01 versus mice treated with saline +
vehicle, saline + imatinib, or MPTP + imatinib; One-Way ANOVA
[F(3.16) = 9.82] followed by Fisher’s PLSD test. (C) Western blot analysis
of striatal levels of DARPP-32-pThr75, DARPP-32-pThr34, and total
DARPP-32 in mice treated with saline + vehicle, saline + imatinib,
MPTP + vehicle, or MPTP + imatinib. Values are means ±S.E.M.
(n = 4–5). ∗P < 0.05 versus mice treated with saline + vehicle, saline +
imatinib, or MPTP + imatinib; One-Way ANOVA [F(3.13) = 4.13] followed
by Bonferroni–Dunn test. (D) Immunohistochemical study on striatal
labeling for DARPP-32-pThr75 in mice treated with saline + vehicle, saline
+ imatinib, MPTP + vehicle or MPTP + imatinib. Representative images
of the striatal sections (0.0–1.0mm anterior to bregma) stained for
DARPP-32-pThr75 from each group are shown. Densitometric analyses
were made on a striatal section from each mouse in a group of saline +
vehicle, saline + imatinib, MPTP + vehicle or MPTP + imatinib. Values
are means ±S.E.M. (n = 5). ∗P < 0.05 versus mice treated with saline +
vehicle, saline + imatinib, or MPTP + imatinib; One-Way ANOVA
[F(3.16) = 5.12] followed by Fisher’s PLSD test.
FIGURE 7 | Hypothesized model of striatal Cdk5/DARPP-32 signal
regulations. Depicted are postsynaptic dopamine/PKA/Thr34-DARPP-32
and glutamate/Cdk5/Thr75-DARPP-32 signaling cascades. c-Abl is the
known kinase to phosphorylate Cdk5 at Tyr15.
would be important in considering the pathophysiology of PD.
Given the novel finding that dopamine signals negatively reg-
ulate expression of Cdk5-pTyr15, an active form of Cdk5, our
present results contribute to a further understanding the mech-
anism by which striatal dopamine deficiency causes parkinsonian
symptoms.
L-Dopa therapy still remains as the gold standard for treat-
ing PD patients; however, it has a potential risk of trouble-
some side-effects such as adverse fluctuations in motor responses
and L-dopa-induced dyskinesias (LIDs) (Calabresi et al., 2010).
Maladaptive synaptic plasticity at glutamatergic synapses cou-
pled with dopamine receptors has been suggested in the devel-
opment of LIDs (Feyder et al., 2011; Murer and Moratalla,
2011). Exploration of new drugs that could exert anti-PD effects
without direct activation of dopamine receptors is therefore
prudent. We suggest the possibility that imatinib and other
c-Abl inhibitors might serve as an alternative and additional
therapeutic tool in treating PD symptoms and PD-associated
LIDs.
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